AveXis (NASDAQ:AVXS) was downgraded by Barclays from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Thursday.
Several other equities analysts have also recently weighed in on AVXS. BidaskClub cut shares of AveXis from a “hold” rating to a “sell” rating in a research report on Thursday, December 14th. Canaccord Genuity set a $110.00 price target on shares of AveXis and gave the company a “hold” rating in a research report on Thursday, December 14th. Citigroup set a $132.00 price target on shares of AveXis and gave the company a “buy” rating in a research report on Friday, January 5th. UBS set a $122.00 price target on shares of AveXis and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Morgan Stanley set a $120.00 target price on shares of AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $123.90.
Shares of NASDAQ AVXS opened at $211.85 on Thursday. AveXis has a fifty-two week low of $65.54 and a fifty-two week high of $213.70. The stock has a market capitalization of $7,774.49, a P/E ratio of -29.10 and a beta of 2.06.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). equities analysts expect that AveXis will post -7.63 earnings per share for the current year.
In related news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $119.50, for a total value of $1,792,500.00. Following the sale, the insider now owns 1,767,766 shares of the company’s stock, valued at approximately $211,248,037. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $126.19, for a total transaction of $224,618.20. The disclosure for this sale can be found here. Insiders sold a total of 68,780 shares of company stock worth $8,341,178 in the last ninety days. 18.60% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of AVXS. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of AveXis by 57.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after purchasing an additional 453 shares during the period. QS Investors LLC bought a new stake in shares of AveXis in the 4th quarter worth approximately $156,000. Cubist Systematic Strategies LLC raised its holdings in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the period. Vident Investment Advisory LLC bought a new stake in shares of AveXis in the 3rd quarter worth approximately $245,000. Finally, Public Employees Retirement Association of Colorado bought a new stake in shares of AveXis in the 4th quarter worth approximately $251,000. 82.43% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/12/avexis-avxs-downgraded-to-equal-weight-at-barclays.html.
AveXis Company Profile
AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.